iShares Biotechnology ETF
IBB
829 hedge funds and large institutions have $4.57B invested in iShares Biotechnology ETF in 2022 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 228 increasing their positions, 305 reducing their positions, and 73 closing their positions.
1.1% more ownership
Funds ownership: 60.56% → 61.66% (+1.1%)
3% less capital invested
Capital invested by funds: $4.68B → $4.57B (-$120M)
3% less funds holding
Funds holding: 858 → 829 (-29)
7% less funds holding in top 10
Funds holding in top 10: 15 → 14 (-1)
23% less first-time investments, than exits
New positions opened: 56 | Existing positions closed: 73
25% less repeat investments, than reductions
Existing positions increased: 228 | Existing positions reduced: 305
64% less call options, than puts
Call options by funds: $257M | Put options by funds: $721M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$76.3M |
| 2 |
GI
Gradient Investments
Arden Hills,
Minnesota
|
+$34M |
| 3 |
Barclays
London,
United Kingdom
|
+$32.7M |
| 4 |
IUHSA
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
|
+$26.4M |
| 5 |
CB
Commerce Bank
Kansas City,
Missouri
|
+$23.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$130M |
| 2 |
Citigroup
New York
|
-$61.5M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$51.8M |
| 4 |
E
Ergoteles
New York
|
-$39M |
| 5 |
Goldman Sachs
New York
|
-$28.9M |
IBB Hedge Fund Activity: Q3 2022 in Review
829 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q3 2022, worth a combined $4.57B — down 2.6% from $4.68B a quarter earlier.
Sellers outnumbered buyers: 73 funds closed out of IBB and 56 opened new positions — a net loss of 17 holders — while 305 trimmed existing stakes and 228 added.
The largest buyer was Morgan Stanley, adding an estimated $76.3M. The largest seller was Bank of America, cutting an estimated $130M.
- 829 institutional investors held iShares Biotechnology ETF (IBB) as of Q3 2022, down from 858 in Q2 2022.
- Funds reported $4.57B of iShares Biotechnology ETF stock for Q3 2022, down 2.6% quarter-over-quarter.
- 56 funds opened new iShares Biotechnology ETF positions in Q3 2022 and 73 closed out, a net change of -17 holders.
- The largest iShares Biotechnology ETF buyer in Q3 2022 was Morgan Stanley, an estimated $76.3M added.
- The largest iShares Biotechnology ETF seller in Q3 2022 was Bank of America, an estimated $130M sold.
Based on aggregated 13F filings for Q3 2022.